BTIG analyst Robert Hazlett maintained a Buy rating on COMPASS Pathways on Thursday, setting a price target of $63, which is approximately 108.89% above the present share price of $30.16.
Hazlett expects COMPASS Pathways to post earnings per share (EPS) of -$0.35 for the third quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in COMPASS Pathways, with an average price target of $72.38.
The analysts price targets range from a high of $100 to a low of $50.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $0 and a net profit of -$12.05 million. The company’s market cap is $1.24 billion.
According to TipRanks.com, BTIG analyst Robert Hazlett is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 17.9% and a 37.61% success rate.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.